BREAKING: Trump Mulls 'Winding Down' Iran War; Stocks Jump Late While investors were spooked by oil-shock prospects, a few stocks continued to hover near new highs. They were also near their latest buy points in Friday's stock market. Two are biotech names. Stock Market: Two Biotech Stocks Hover Near Highs | Investor's Business Daily United Therapeutics (UTHR) jumped to an all-time high of 548.12 on March 10 and has pulled back to a buy zone above a 519.99 entry. United Therapeutics develops treatments for ...

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with stron ...

Core Insights - United Therapeutics Corporation is a biotechnology company focused on developing products for chronic and life-threatening conditions, particularly in pulmonary arterial hypertension [1] Insider Transactions - Martine A. Rothblatt, Chairperson and CEO, sold 516 shares at approximately $534.99 each, leaving her with 8,414 shares [2][6] - Ray Kurzweil, Director, sold 4,910 shares at an average price of $489.02, reducing his holdings by 27.93% to 12,670 shares, valued at around $6.2 million [2][3][6] - Paul Mahon, Executive Vice President, sold 8,300 shares at an average price of $483.16, totaling over $4 million, marking an 18.39% reduction in his holdings, leaving him with 36,844 shares valued at approximately $17.8 million [3][6] Stock Performance - United Therapeutics' stock opened at $478.16, reflecting a 1.4% decrease, with a 50-day simple moving average of $482.51 and a 200-day simple moving average of $452.28 [4] - The company has a market capitalization of approximately $21 billion, a price-to-earnings ratio of 17.14, and a price-to-earnings-growth ratio of 1.75 [4] - The stock has experienced a 12-month low of $266.98 and a high of $537.19, with a price-to-sales ratio of about 7.38 and an enterprise value to sales ratio of around 6.89 [5] Financial Health - United Therapeutics has a strong current ratio of 6.60, indicating its ability to cover short-term liabilities with short-term assets [5] - The earnings yield is approximately 5.62%, reflecting the earnings generated from each dollar invested in the stock [5]

Core Insights - United Therapeutics (UTHR) shares have increased approximately 32% over the past six months due to strong commercial growth, a significant clinical breakthrough, and enhanced long-term growth visibility, boosting investor confidence [1] Financial Performance - UTHR reported better-than-expected earnings for Q4 2025, with annual revenues nearing $3.2 billion, primarily driven by the rapid adoption of its flagship drug Tyvaso, especially the dry-powder inhaler (DPI) version [2][3] - The company ended 2025 with $4.6 billion in cash and no debt, indicating strong financial health [8][11] - UTHR anticipates double-digit revenue growth in 2026 and aims to reach a $4 billion annual revenue run-rate in the second half of 2027 [12] Product Performance - Tyvaso has become the primary growth engine for United Therapeutics, with combined sales growing 16% year over year in 2025, and Tyvaso DPI sales increasing by 25% year over year [3] - Positive data from the Phase III TETON-2 study showed significant improvements in lung function for patients with idiopathic pulmonary fibrosis (IPF), which could expand Tyvaso's therapeutic reach and revenue potential [5][6] Pipeline Developments - United Therapeutics is conducting the Phase III TETON-1 study of nebulized Tyvaso in IPF patients, with data expected in early 2026, and plans to expedite regulatory review with the FDA [9] - The company is also evaluating ralinepag for PAH in the Phase III ADVANCE OUTCOMES study, which met its primary endpoint, with a new drug application planned for submission in the second half of 2026 [10] Market Performance - Over the past year, UTHR shares have rallied 73.4%, significantly outperforming the industry, which saw a 1.6% decline [4]

Core Insights - United Therapeutics Corporation announced the full results of the TETON-2 Phase 3 clinical trial for nebulized Tyvaso (treprostinil), demonstrating significant preservation of lung function and reduction in clinical worsening events in patients with idiopathic pulmonary fibrosis (IPF) [1][2] Study Results - The TETON-2 study met its primary efficacy endpoint, showing a statistically significant improvement in absolute forced vital capacity (FVC) from baseline to week 52, with a median change of 49.9 mL in the Tyvaso group compared to 136.4 mL in the placebo group, resulting in a between-group difference of 95.6 mL (P<0.001) [1][2] - Nebulized Tyvaso reduced the risk of clinical worsening events by 29% (hazard ratio 0.71; P=0.02) compared to placebo, achieving statistical significance in this key secondary endpoint [1][2] - Improvements were also noted in secondary endpoints, including change in percent predicted FVC, quality of life as measured by the King's Brief Interstitial Lung Disease questionnaire (K-BILD), and diffusion capacity of lungs for carbon monoxide (DLCO) [1][2] Patient Population and Safety - The trial included 597 patients with a mean age of 71.7 years, 80.1% male, and 75.4% on background antifibrotic therapy, reflecting a general population of IPF patients [1][2] - Treatment with nebulized Tyvaso was well-tolerated, with adverse events primarily being cough, headache, and diarrhea, consistent with previous studies [1][2] Regulatory Plans - United Therapeutics plans to submit a supplemental New Drug Application (sNDA) to the FDA by the second half of 2026 to add IPF to the labeled indications for nebulized Tyvaso [1][2] Background on IPF and Tyvaso - Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterized by scarring of lung tissue, leading to respiratory failure and death, affecting an estimated 100,000 patients in the United States [2] - Tyvaso is currently indicated for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [2][3]

Core Viewpoint - The article emphasizes the importance of conducting thorough research and independent verification before making investment decisions, highlighting the inherent volatility and risks associated with stock investments [2][3]. Group 1 - The article provides informational content but does not serve as an exhaustive analysis of any featured company [2]. - It clarifies that the financial models presented are based on the author's assumptions and are sensitive to input changes, which can significantly alter outputs [2]. - The predictions and opinions expressed reflect a probabilistic approach rather than absolute certainty, indicating the need for caution [2]. Group 2 - The article states that past performance is not a guarantee of future results, underscoring the unpredictability of investment outcomes [3]. - It notes that no recommendations or advice are provided regarding the suitability of investments for particular investors [3]. - The authors of the article include both professional and individual investors, who may not be licensed or certified, which could affect the reliability of the insights provided [3].

Group 1 - United Therapeutics (UTHR) shares increased by 10.7% to close at $529.17, following a trading session with notable volume, contrasting with a 1.5% loss over the past four weeks [1] - The rise in shares is attributed to the announcement of a new $2 billion buyback program, which includes an initial $1.5 billion accelerated share repurchase agreement with Citibank, and up to $500 million available for additional repurchases at the company's discretion [2] - The company is expected to report quarterly earnings of $6.72 per share, reflecting a year-over-year increase of 1.4%, with revenues projected at $809.15 million, up 1.9% from the previous year [3] Group 2 - The consensus EPS estimate for United Therapeutics has been revised 4.1% lower over the last 30 days, indicating a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [4] - United Therapeutics holds a Zacks Rank of 3 (Hold), while Korro Bio, Inc. (KRRO), another company in the same industry, closed 10% higher at $12.3 but has returned -11.1% over the past month [4] - Korro Bio, Inc. has an unchanged consensus EPS estimate of -$1.93 for the upcoming report, representing a 14.6% change from the previous year, and currently holds a Zacks Rank of 4 (Sell) [5]

Core Insights - United Therapeutics focuses on two progressive fatal illnesses: pulmonary hypertension and pulmonary fibrosis, reporting the best clinical trial results in these diseases since the FDA's inception [1]. Group 1: Company Overview - The main pillars of United Therapeutics' strategy are centered around addressing pulmonary hypertension and pulmonary fibrosis [1]. - The company has achieved significant clinical trial results this year, marking a milestone in the treatment of these diseases [1].

Summary of United Therapeutics Conference Call Company Overview - **Company**: United Therapeutics (NasdaqGS: UTHR) - **Focus**: Development of treatments for pulmonary hypertension and pulmonary fibrosis, with significant clinical trial results reported recently [3][5] Key Points Clinical Trial Results - United Therapeutics reported the best clinical trial results for pulmonary fibrosis and pulmonary hypertension in the history of FDA approvals [3][5] - **Pulmonary Hypertension**: Approximately 50,000 patients in the U.S. suffer from this condition, with untreated patients having a five-year mortality rate [5] - **Pulmonary Fibrosis**: Estimated 100,000 patients in the U.S. are affected, with similar mortality risks [5] - The company’s drug **TYVASO** showed significant improvement in patients' Forced Vital Capacity (FVC), outperforming all previously approved medications [5][6] - **Ralinepag**, another drug, demonstrated superior efficacy in slowing clinical worsening compared to existing oral treatments for pulmonary hypertension [6][7] Market Potential - United Therapeutics anticipates that **TYVASO** will become the primary treatment for pulmonary fibrosis, potentially reaching 15,000 patients within two years post-launch, correlating to approximately $3 billion in revenue [12] - The peak revenue for ralinepag could be significantly higher, with projections suggesting it could reach 20 times the initial launch revenue by the 2030s [13][19] - The company expects to file for FDA approval for ralinepag in mid-2026, with a quick launch thereafter [11][12] Product Development and Innovations - United Therapeutics is developing a **soft mist inhaler** (Trezist) that significantly reduces cough in patients, with a 90% reduction reported in initial studies [32] - The company plans to file for approval of Trezist in 2026, with a launch expected in 2027 [31][32] - Future products include a once-daily inhaler and a PRN inhaler for pulmonary hypertension, aimed at improving patient convenience and adherence [40][41] Xenotransplantation and Organ Manufacturing - United Therapeutics is advancing in xenotransplantation with two active xenokidney INDs, focusing on normal kidney function and lack of rejection signs in early clinical trials [47] - The company plans to submit data from the first six patients to the FDA by Q3 2028, with potential approval for the first xenotransplant product expected in 2029 [52] AI-Enabled Digital Lung Model - The company has developed an AI-enabled digital lung model that has successfully predicted clinical trial outcomes, saving significant costs in drug development [63][66] - This model is being presented to the FDA as supportive evidence for faster and safer drug development processes [68] Additional Insights - United Therapeutics emphasizes its commitment to patient assistance programs, ensuring that no patient is left behind due to financial constraints [12] - The company has a strong reputation in the pulmonary hypertension field, which aids in the acceptance of new treatments by healthcare providers [12] This summary encapsulates the key aspects of United Therapeutics' recent conference call, highlighting their innovative approaches, market potential, and commitment to patient care.

Core Viewpoint - United Therapeutics Corporation has initiated a stock repurchase program with a total authorization of up to $2 billion for buybacks over the next year [1] Group 1: Stock Repurchase Program - The board of directors of United Therapeutics Corporation has approved a stock repurchase program [1] - The company plans to execute buybacks amounting to $2 billion within the next year [1] Group 2: ASR Agreements - United Therapeutics has entered into Accelerated Share Repurchase (ASR) agreements with Citibank [1] - The initial ASR agreement is valued at $1.5 billion [1]